Gabapentin Thame 50 mg/ml oral solution
Authorisation PA22697/025/001 · Syri Pharma Limited t/a Thame Laboratories
- Licence holder
- Syri Pharma Limited t/a Thame Laboratories (all products →)
- Active substance
- Gabapentin
- Clinical trials
- 12 clinical trials →
- Dosage form
- Oral solution
- Route of administration
- Oral use
- ATC code
- N02BF01
- First authorised
- 27/06/2025
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- Hybrid application (Article 10(3) of Directive No 2001/83/EC)
Gabapentin: supply and approvals
24 authorised products on the HPRA list contain Gabapentin. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- 12 supply notices, e.g. Gabapentin Aurobindo 800 mg Filmtabletten (3 Nov 2026 to 15 Mar 2027)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 1 year (since 27 June 2025). The HPRA list marks it as marketed in Ireland.
Other medicines with Gabapentin in Ireland
23 other products on the HPRA list contain Gabapentin, from 6 licence holders; 10 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Gabapentin Rosemont 50 mg/ml Oral Solution | Taw Pharma (Ireland) Limited | National authorisation (PA) | Marketed |
| Gabin 100 mg capsules, hard | Aurobindo Pharma (Malta) Limited | National authorisation (PA) | Marketed |
| Gabin 300 mg capsules, hard | Aurobindo Pharma (Malta) Limited | National authorisation (PA) | Marketed |
| Gabin 400 mg capsules, hard | Aurobindo Pharma (Malta) Limited | National authorisation (PA) | Marketed |
| Neurontin 100 mg hard capsules | Viatris Healthcare Limited | National authorisation (PA) | Marketed |
| Neurontin 300 mg hard capsules | Viatris Healthcare Limited | National authorisation (PA) | Marketed |
| Neurontin 400 mg hard capsules | Viatris Healthcare Limited | National authorisation (PA) | Marketed |
| Neurontin 600 mg film-coated tablets | Viatris Healthcare Limited | National authorisation (PA) | Marketed |
| Neurontin 800 mg film-coated tablets | Viatris Healthcare Limited | National authorisation (PA) | Marketed |
| Neurostil 300 mg hard capsules | Teva B.V. | National authorisation (PA) | Marketed |
| Gabapentin 100 mg hard capsules | Accord Healthcare Ireland Ltd. | National authorisation (PA) | Not marketed |
| Gabapentin 300 mg hard capsules | Accord Healthcare Ireland Ltd. | National authorisation (PA) | Not marketed |
The licence holder
Syri Pharma Limited t/a Thame Laboratories holds 23 products on the HPRA list, with 17 different active substances; 8 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.